Decheng Capital Global Life Sciences Fund IV, L.P.

CIK: 0001834150

Transaction Breakdown

Open Market Buys (P)2 (50.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)0 (0.0%)

Compensation grants

Other (G, F, J, C, D, …)2 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

AARD

Aardvark Therapeutics, Inc.

10% Owner

Discretionary Trading P&L

Holdings

Transaction History (4 total)

AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Conversion(C)
Indirect
2.3M shares-
AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Conversion(C)
Indirect
333.4K shares-
AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Purchase(P)
Indirect
625K shares at avg. $16.00$10.0M
AARD
Aardvark Therapeutics, Inc.
Feb 14, 2025
Purchase(P)
Indirect
625K shares at avg. $16.00$10.0M

		Type	Shares	Price		Ownership
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Conversion(C)	2,333,887	-	-	Indirect
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Conversion(C)	333,412	-	-	Indirect
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	625,000	$16.00	$10,000,000	Indirect
Feb 14, 2025	AARD Aardvark Therapeutics, Inc.	Purchase(P)	625,000	$16.00	$10,000,000	Indirect

1-4 of 4 transactions

About Decheng Capital Global Life Sciences Fund IV, L.P.

Decheng Capital Global Life Sciences Fund IV, L.P. (SEC CIK 0001834150) files insider reports with the SEC as 10% Owner of Aardvark Therapeutics, Inc. (AARD).

Signal8 holds 2 ownership filings by Decheng Capital Global Life Sciences Fund IV, L.P. (1 Form 3, 1 Form 4), filed between Feb 12, 2025 and Feb 19, 2025. Those filings report 4 transactions, the latest on Feb 14, 2025. Signal8's Form 4 history starts in Sep 2024.

The business address on Decheng Capital Global Life Sciences Fund IV, L.P.'s filings is in GRAND CAYMAN, E9.

Recent filings by Decheng Capital Global Life Sciences Fund IV, L.P.

Feb 14, 2025: Conversions of AARD shares (2 lines, Form 4, code C).
Feb 14, 2025: Open-market purchases of AARD shares (2 lines, Form 4, code P).

Other insiders filing for Aardvark Therapeutics, Inc. (AARD)

Zhang Zhongwei, Director
Sun Nelson
Chi Jeffrey, Director
Graf Susan E, Director
Baynes Roy D., Director
Tong Victor Edward Jr, Director

How to read Form 4 transaction codes